Amgen’s Leukemia Drug Gets Full FDA Approval

Late Tuesday, Amgen (AMGN) announced that the Food and Drug Administration gave its approval to the company’s supplemental biologics license application regarding its leukemia drug, bispecific antibody  Blincyto, converting its accelerated approval to a full approval. Getty Images Oppenheimer’s Leah Rush Cann reiterated an Outperform rating and $189 price target on the stock following the report. She writes […]
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>